发明名称 |
Antibodies directed to angiopoietin-2 and uses thereof |
摘要 |
Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies. |
申请公布号 |
US8834880(B2) |
申请公布日期 |
2014.09.16 |
申请号 |
US201213690120 |
申请日期 |
2012.11.30 |
申请人 |
MedImmune Limited |
发明人 |
Green Larry L.;Zhou Qing;Keyt Bruce A.;Yang Xiao-Dong;Emery Stephen Charles;Blakey David Charles |
分类号 |
A61K39/395;C07K16/22 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating Angiopoietin-2 induced angiogenesis, comprising administering to an animal in need thereof a therapeutically effective dose of a monoclonal antibody that binds Angiopoietin-2 (Ang-2), wherein the animal in need suffers from an angiogenesis-related disease, and wherein the antibody is selected from the group consisting of:
a) an antibody comprising the heavy chain CDR1, CDR2 and CDR3 of SEQ ID NO:79, and the light chain CDR1, CDR2 and CDR3 of SEQ ID NO: 81; and b) an antibody comprising a variable heavy chain sequence with 90% identity to SEQ ID NO:79 and a variable light chain sequence with 90% identity to SEQ ID NO:81,wherein angiogenesis is inhibited. |
地址 |
Cambridge GB |